Predictive value of preclinical toxicology studies for platinum anticancer drugs

Clinical Cancer Research

Volumn 5, Issue 5, 1999, Pages 1161-1167

  Clark, Diana L ^a   Andrews, Paul A ^a   Smith, David D ^a   DeGeorge, Joseph J ^a   Justice, Robert L ^a   Beitz, Julie G ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; ENLOPLATIN; IPROPLATIN; LOBAPLATIN; OXALIPLATIN; PLATINUM DERIVATIVE; SATRAPLATIN; SEBRIPLATIN; SPIROPLATIN; TETRAPLATIN; ZENIPLATIN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; HUMAN; LD 50; MOUSE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EVALUATION STUDIES; HUMANS; MICE; ORGANOPLATINUM COMPOUNDS; RATS; SINGLE-BLIND METHOD; SPECIES SPECIFICITY; TOXICITY TESTS;

EID: 0032901634     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. DeGeorge, J. J., Ahn, C-H., Andrews, P. A., Brower, M. E., Giorgio, D. W., Goheer, M. A., Lee-Ham, D. Y., McGuinn, W. D., Schmidt, W., Sun, C. J., and Tripathi, S. C. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother. Pharmacol., 41: 173-185, 1998.
2. Grieshaber, C. K., and Marsoni, S. Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat. Rep., 70: 65-72, 1986.
3. Lowe, M. C., and Davis, R. D. The current toxicology protocol of the National Cancer Institute. In: K. Hellmann and S. K. Carter (eds.), Fundamentals of Cancer Chemotherapy, pp. 228-235. New York: McGraw-Hill, 1984.
4. Burtles, S. S., Newell, D. R., Henrar, R., and Connors, T. A. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur. J. Cancer, 31A: 408-410, 1995.
5. Connors, T. A., and Pinedo, H. M. Drug development in Europe. In: B. A. Teicher (ed.), Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials and Approval, pp. 271-288. Totowa, NJ: Humana Press, 1997.
6. Burtles, S. S., Jodrell, D. I., and Newell, D. R. Evaluation of "rodent-only" preclinical toxicology for phase I trials of new cancer treatment - the Cancer Research Campaign (CRC) experience. Proc. Am. Assoc. Cancer Res., 39: 363, 1998.
7. Koeller, J. M., Trump, D. L., Tutsch, K. D., Earhart, R. H., Davis, T. E., and Tormey, D. C. Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion. Cancer (Phila.), 57: 222-225, 1986.
8. 1) platinum in patients with metastatic solid tumors. Cancer Chemother. Pharmacol, 31: 333-337, 1993.
9. DeConti, R. C., Toftness, B. R., Lange, R. C., and Creasey, W. A. Clinical and pharmacological studies with cis-diamminedichloroplatinum(II). Cancer Res., 33: 1310-1315, 1973.
10. Ceulemans, F., Trouet, A., Duprez, P., Vindevogel, A., Alaerts, P., Hammershaimb, L., Saletan, S., and Rastogi, R. Phase I study of a new water soluble platinum containing antitumor agent CL 287,110 (CL) in advanced cancer patients (pts.). Proc. Am. Assoc. Cancer Res., 30: 283, 1989.
11. Creaven, P. J., Madajewicz, S., Pendyala, L., Mittelman, A., Pontes, E., Spaulding, M., Arbuck, S., and Solomon, J. Phase I clinical trial of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum(IV) (CHIP). Cancer Treat. Rep., 67: 795-800, 1983.
12. McKeage, M. J., Mistry, P., Ward, J., Boxall, F. E., Loh, S., O'Neill, C., Ellis, P., Kelland, L. R., Morgan, S. E., Murrer, B., Santabarbara, P., Harrap, K. R., and Judson, I. R. A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemother. Pharmacol., 36: 451-458, 1995.
13. Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., Al-Baker, S., Francis, K., Macias-Kiger, D., Raber, M. N., and Khokhar, A. R. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(II). Cancer Res., 50: 4254-4259, 1990.
14. Fiebig, H. H., Mross, K., Henss, H., Ludolph, D., Meyberg, F., Aulenbacher, P., and Queisser, W. Phase I clinical trial of lobaplatin (p-19466) after intravenous bolus injection. Onkologie, 17: 142, 1994.
15. Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25: 299-303, 1990.
16. Tanis, B. C., Vermorken, J. B., Ten Bokkel Huinink, W. W., Klein, I., Gall, H., van Oosterom, A. T., Simonetti, G., McVie, J. G., van der Vijgh, W. J. F., and Pinedo, H. M. Phase I study of spiroplatin. Eur J. Cancer, 27: 268-273, 1991.
17. O'Rourke, T. J., Weiss, G. R., New, P., Burris, H. A., Rodriguez, G., Eckhardt, J., Hardy, J., Kuhn, J. G., Fields, S., Clark, G. M., and Von Hoff, D. D. Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812). Anticancer Drugs, 5: 520-526, 1994.
18. Dodion, P. F., de Valeriola, D., Crespeigne, N., Kantrowitz, J. D., Piccart, M., Wery, F., Kerger, J., Egorin, M. J., Forrest, A., Bachur, N. R., Alaerts, P., Carver, A., Rastogi, R., Hamershaimb, L., and Saletan, S. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex. Ann. Oncol., 2: 589-596, 1991.
19. Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., and Skipper, H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep., 50: 219-244, 1966.
20. Grieshaber, C. K. Prediction of human toxicity of new antineoplastic drugs from studies in animals. In: G. Powis and M. P. Hacker (eds.), The Toxicity of Anticancer Drugs, pp. 10-27. New York: Pergamon Press, 1991.
21. Lowe, M. C. Large animal toxicological studies of anticancer drugs. In: K. Hellmann and S. K. Carter (eds.), Fundamentals of Cancer Chemotherapy, pp. 236-247. New York: McGraw-Hill, 1987.
22. Lelieveld, P., van der Vijgh, W. J. F., and van Velzen, D. Preclinical toxicology of platinum analogues in dogs. Eur. J. Cancer Clin. Oncol., 23: 1147-1154, 1987.
23. Collins, J. M., Grieshaber, C. K., and Chabner, B. A. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst., 82: 1321-1326, 1990.
24. Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S. G., Collins, J., and Christian, M. C. Accelerated titration designs for phase I clinical trials in oncology. J. Natl. Cancer Inst., 89: 1138-1147, 1997.
25. Faries, D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J. Biopharm. Stat., 4: 147-164, 1994.
26. Collins, J. M., Zaharko, D. S., Dedrick, R. L., and Chabner, B. A. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep., 70: 73-80, 1986.
27. EORTC Pharmacokinetics, and Metabolism Group. Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur. J. Cancer Clin. Oncol., 23: 1083-1087, 1987.
28. Mani, S., and Ratain, M. J. New phase I trial methodology. Semin. Oncol., 24: 253-261, 1997.
29. Verweij, J. Starting dose levels for phase I studies. Ann. Oncol., 7: 13, 1996.